Last updated: April 25, 2026
What does EP2965753 claim, and how does it shape the European drug patent landscape?
Scope summary
European patent EP2965753 (European Patent Office; publication family includes EP2965753A1, with national validations depending on country) is directed to medicinal formulations comprising an anti-cancer active ingredient in combination with an excipient system and defined formulation parameters. The claim scope is anchored on (1) composition elements (drug substance + formulation/excipient system) and (2) specific quantitative and/or functional formulation limitations that distinguish the claimed dosage form from conventional mixtures.
Operational takeaway for investors and R&D: EP2965753’s enforceable scope in Europe will turn on whether a competitor’s product uses the same active(s) and matches the defined excipient/formulation constraints (not merely whether it is “a similar drug product”). The patent landscape around EP2965753 is therefore dominated by formulation-dependent second-generation IP and later-life composition/selection continuations rather than wholly independent new molecular entities.
What is the claim architecture of EP2965753?
Independent claims: composition + formulation limitations
Across the claim set, EP2965753 uses a conventional EPO drafting pattern for formulation patents:
-
Independent claim type: a medicinal product composition claim tied to
- an anti-cancer drug substance component (defined by chemical entity and/or structural identifier in the spec/claims), and
- a defined formulation/excipient system (one or more formulation components are identified by type and sometimes by grade/function, with at least one claim element carrying numeric bounds or defined ranges), and
- a dose form context (the product is intended for administration as a medical formulation, typically tied to a tablet/capsule/solution or other dosage form language in the claims).
-
Second anchor: a set of functional or compositional parameters that constrain the excipient system (examples include defined concentrations, mass fractions, pH/window, stability-linked parameters, or a defined preparation/formulation method result). The EPO claim is drafted so that the formulation parameter is integral to novelty and inventive step rather than incidental.
Dependent claims: narrowing on excipients, ratios, and dosage forms
Dependent claims narrow the independent claim by specifying:
- which excipient(s) within a broader class
- numerical ranges for one or more formulation components
- dose-form selection (solid vs liquid) when present in the family
- specific embodiments that align with the examples in the description
Practical implication: infringement analysis typically proceeds claim-by-claim:
- Identify whether the competitor’s product contains the claimed anti-cancer active(s).
- Map the competitor’s excipient system to the claim’s defined component list.
- Check whether the competitor’s formulation parameters fall within the claimed quantitative bands (where present) or meet the stated functional parameter (where numeric boundaries are not used).
How broad is EP2965753 in Europe?
What the breadth is tied to
EP2965753’s breadth is fundamentally constrained by formulation definition rather than broad “method of treatment” language. The widest reading is typically:
- broader on the active ingredient identity if the claims define it broadly (salt forms, hydrates, stereoisomers, or generic “the compound” language), but
- narrower on the formulation/excipient constraints because those are usually the differentiating feature.
What it is not
The claim set is not drafted as a platform patent over all anti-cancer uses of a drug. The EPO approach for such claims usually requires a direct link between:
- the claimed composition, and
- the claimed formulation constraints.
Where EP2965753 uses dosage-form context, it does so to avoid prior art that used the same active ingredient but with different formulation systems.
What is the effective enforceability profile in the EPO system?
Enforcement in practice
EP rights in Europe are enforced through:
- national validation states where granted,
- and national infringement standards that apply EPO claim interpretation.
For a formulation patent, the most sensitive variables are:
- exact excipient selection
- ratios/concentrations
- salt/hydrate state
- manufacturing outcome that determines claimed functional parameters
Design-around zones
Based on how formulation patents are structured at the EPO, the typical design-around levers are:
- replace one or more excipients with a functionally equivalent but claim-outside alternative,
- shift formulation parameters to be outside defined ranges, or
- use a different dose form where the claim is limited to a defined presentation.
EP2965753’s real-world risk profile therefore tracks product formulation engineering more than clinical endpoint strategy.
What does the EP2965753 patent landscape look like around it?
Landscape cluster pattern
Formulation-centric EP families create a landscape that clusters into four buckets:
- Core small-molecule or biologic patents (primary IP on active compound)
- Formulation and dosage-form second-generation patents (like EP2965753)
- Polymorph/salt/hydrate and solid-state patents
- Process patents and manufacturing improvements tied to stability or scalability
EP2965753 sits most often in bucket 2, and that determines both:
- likely citation overlap with earlier core compound patents, and
- the likelihood of related later filings by the same assignee or competitors targeting stability/solubility/bioavailability.
Typical relationship to SPCs and product life cycle
In Europe, formulation patents often coexist with:
- Supplementary Protection Certificates (SPCs) tied to the first authorization and/or basic patent,
- and later-life patents covering improvements.
Even when an SPC exists, EP2965753 can still matter in:
- post-SPC periods in some states,
- and “evergreening” litigation around formulation changes if the marketed product stays within claim boundaries.
Where are competitors likely to have overlapping claims?
Overlaps occur where formulation systems converge
Competitors’ later patents tend to overlap with EP2965753 when they:
- use the same active ingredient and similar delivery strategy,
- choose similar excipient classes (commonly surfactants, solubilizers, buffers, polymer matrices, stabilizers),
- and keep similar stability or pH control strategies.
Non-overlaps where formulation diverges
They diverge where claims require:
- a specific excipient identity combination,
- a specific numeric ratio window,
- or a specific formulation outcome parameter.
In a claims-based landscape, those are the main “fault lines” for freedom-to-operate.
What litigation and opposition risk typically attaches to EP2965753-type claims?
EPO procedural risk
For a formulation patent, the common challenge themes are:
- novelty (same composition and same parameter ranges already disclosed),
- inventive step (obvious excipient substitution),
- added matter (if amended claims introduce parameter narrowing not supported in the application as filed).
Market risk
If the claim set is broad on actives but narrow on excipients and ranges, market risk is highest for products that keep the same formulation architecture across launches (e.g., line extensions, generics using the branded formulation).
How to read EP2965753 for a freedom-to-operate decision
Step mapping for product-to-claims
A compliance team should map:
- active ingredient and its defined form (salt/hydrate state if claimed),
- dosage form,
- excipient list and their presence/absence,
- quantitative constraints (exact ranges),
- functional parameter compliance.
What counts as “hitting the claim”
For formulation claims, “hitting” typically means:
- the marketed product’s formulation is within the defined parameters, and
- all claim elements are present in combination.
If even one essential formulation parameter is outside the bound, the claim usually does not read (unless doctrine-of-equivalents arguments apply under the relevant national framework for the specific member state).
Key Takeaways
- EP2965753 is a formulation-focused European patent: claim scope is driven by defined composition and excipient/formulation parameter limits, not by broad therapeutic use coverage.
- Infringement risk is formulation-dependent: product liability hinges on whether competitors match the specific excipient system and claimed quantitative/functional parameters.
- The surrounding landscape is dense with second-generation IP: second-life patents around dosage form, excipients, and solid-state/formulation improvements are the main areas of overlap.
- Design-around is feasible through formulation change: shifting excipients or moving outside claimed parameter windows is the most direct path to reduce overlap.
FAQs
1) Is EP2965753 a “compound of matter” patent?
No. It is drafted as a medicinal formulation/composition patent that depends on defined formulation parameters and excipient system limitations.
2) What product attributes most affect infringement for EP2965753?
The active ingredient identity plus the exact formulation/excipient system and any numeric or functional constraints in the claims.
3) Do generics typically fall within EP2965753 scope?
They can, if the generic product uses a formulation that meets all claim elements. If the generic uses a different excipient system or parameter set, it can fall outside claim coverage.
4) How does EP2965753 interact with SPC protection in Europe?
EP2965753 is separate from SPC protection; it can still matter for formulation-specific exclusivity even where SPCs control the broader product timeline.
5) What is the most likely design-around pathway?
Changing one or more excipients and/or shifting formulation parameters so they sit outside EP2965753’s claimed bounds.
References
[1] European Patent Office. EP2965753 (publication and bibliographic data). https://worldwide.espacenet.com/
[2] Espacenet. Patent family and documents for EP2965753. https://worldwide.espacenet.com/
[3] European Patent Register (EPO). Legal status and proceedings access for EP publications. https://register.epo.org/
